BCR-ABL V280G Mutation, Potential Role in Imatinib Resistance: First Case Report

INTRODUCTION: The identification of BCR-ABL expression as the defining leukemogenic event in chronic myeloid leukemia (CML) and the introduction of BCR-ABL tyrosine kinase inhibitors in 2001 have revolutionized disease management, leading to a reduction in mortality rates and accordingly an increase...

Descripción completa

Detalles Bibliográficos
Autores principales: Azevedo, Ana P, Reichert, Alice, Afonso, Celina, Alberca, Maria D, Tavares, Purificação, Lima, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395261/
https://www.ncbi.nlm.nih.gov/pubmed/28469513
http://dx.doi.org/10.1177/1179554917702870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395261/
https://www.ncbi.nlm.nih.gov/pubmed/28469513
http://dx.doi.org/10.1177/1179554917702870

Ejemplares similares